Akers Biosciences, Inc (AKER) - Back in March, the Company, known for its development of rapid health information technologies, announced that it had entered into a three-year National Distribution Agreement with Diagnostica Stago, inc for the sale of the Company's flagship rapid test for Heparin-induced thrombocytopenia across the U.S.
According to a press release issued at the time, John J. Gormally, the Company's chief executive officer commented, ''The addition of Stago to our growing and distinguished distributor network is a significant milestone in the commercialization of PIFA PLUSS PF4™. Stago is a recognized leader in the field of hemostasis and has a very large and established customer base to which to market our product. Through Stago, Akers Bio will gain access to a dedicated and specialized sales team who are focused exclusively on buyers of hemostasis-related products. Akers Bio is excited about the potential for near-term US sales growth through this new, additional and specialized channel to market.''
Looks like a double bottom. Could be ready to move up from here.
At this stage i haven’t added this to my portfolio so importantly, I’m not offering financial advice.
Leave a thumbs up if you agree The forecast and comments.